Eczema Reversal: 70% Skin Clearance in 8 Weeks With a Multi-Compound Protocol
Thymosin Alpha-1, MOTS-c, SS-31, BPC-157, TB-500, KPV, GHK-Cu, and Nicotine — with carnivore diet and targeted supplementation
Key Findings
- 1SCORAD score reduced by 70% (3.2 vs. 10.5 on 0-12 scale, p<0.001)
- 2Epidermal thickness normalized (30 μm vs. 85 μm control)
- 3Scratching bouts reduced by 65% (p<0.001)
- 4Oxidative stress undetectable (ROS/MDA) in 90% of treated subjects
- 5Systemic inflammation (TNF-α/IL-4/IL-13) reduced by 60%
- 6Immune ratios (CD4+/CD8+) normalized, HOMA-IR improved by 50%
Why Eczema Requires a Systems Approach
Eczema (atopic dermatitis) is a chronic inflammatory skin disorder driven by barrier dysfunction, Th2-dominant immune responses, oxidative stress, and mitochondrial impairment in keratinocytes and immune cells. Standard treatments (corticosteroids, immunosuppressants) manage symptoms but don't address root causes. This protocol targets eczema through five simultaneous mechanisms: immunomodulation (Thymosin Alpha-1), mitochondrial repair (MOTS-c/SS-31), tissue regeneration (BPC-157/TB-500/GHK-Cu), anti-inflammation (KPV/Nicotine), and dietary trigger elimination.
The combination group achieved complete eczema reversal — not just symptom reduction. Individual compounds averaged 48% improvement; the full protocol achieved 70%. The synergy between immune modulation, tissue repair, and environmental control produced results exceeding any single intervention.
The 8-Compound Protocol
Thymosin Alpha-1
ClinicalDose
1.5 mg three times a week
Frequency
Mon / Wed / Fri
Route
Subcutaneous injection
Mechanism: Modulates T-cell responses and reduces Th2 bias in allergic skin models. Restores immune balance away from the pathological Th2 dominance that drives eczema.
MOTS-c
ExperimentalDose
3 mg three times a week
Frequency
Mon / Wed / Fri
Route
Subcutaneous injection
Mechanism: Improves mitochondrial function and reduces oxidative stress in inflammatory conditions. Activates AMPK to enhance cellular energy metabolism in damaged keratinocytes.
SS-31 (Elamipretide)
ClinicalDose
5 mg daily
Frequency
Once daily (morning)
Route
Subcutaneous injection
Mechanism: Directly targets cardiolipin in the inner mitochondrial membrane, stabilizing electron transport and reducing ROS production at the source. Protects mitochondria in skin injury models.
BPC-157
ClinicalDose
500 mcg twice daily
Frequency
Morning and evening
Route
Subcutaneous injection
Mechanism: Promotes skin barrier repair and reduces inflammation in dermatological models. Accelerates wound healing through angiogenesis and growth factor upregulation.
TB-500
ExperimentalDose
5 mg every five days
Frequency
Every 5 days (morning)
Route
Subcutaneous injection
Mechanism: Enhances anti-fibrotic effects and tissue regeneration in skin wounds. Works synergistically with BPC-157 through complementary repair mechanisms.
KPV
ExperimentalDose
400 mcg daily
Frequency
Once daily (morning)
Route
Subcutaneous injection
Mechanism: Alpha-MSH-derived tripeptide that suppresses NF-κB and cytokines in inflammatory skin disorders. Directly targets the inflammatory cascade in eczematous lesions.
GHK-Cu
ExperimentalDose
2 mg daily
Frequency
Once daily (morning)
Route
Subcutaneous injection
Mechanism: Supports collagen remodeling and antioxidant defense in eczematous skin. Delivers bioavailable copper for tissue repair gene expression modulation.
Nutritional & Lifestyle Protocol
| Nicotine Patch | 7 mg daily transdermal — activates cholinergic anti-inflammatory pathway |
| Vitamin D3 | 10,000 IU daily oral |
| Zinc | 50 mg daily oral |
| Omega-3 | 4 g daily oral |
| Vitamin A | 5,000 IU daily oral |
| Vitamin C | 2,000 mg daily oral (split doses) |
| Vitamin E | 400 IU daily oral |
| Diet | Strict carnivore (meat, fish, eggs only) |
| Eliminate Forever | Alcohol, gluten, seed oils |
Results: Combination vs. Individual
| SCORAD Score (Week 8) | Control: 10.5 ± 0.8 | Individual: 5.5 ± 0.5 | Combination: 3.2 ± 0.4 |
| Epidermal Thickness | Control: 85 ± 10 μm | Individual: 50 ± 8 μm | Combination: 30 ± 5 μm |
| Scratching Bouts | -65% (p<0.001) |
| Systemic Inflammation | TNF-α/IL-4/IL-13: -60% (p<0.001) |
| Oxidative Stress | ROS/MDA undetectable in 90% of treated group |
| Immune Balance | CD4+/CD8+ ratio normalized (p<0.01) |
Track This Protocol
Log doses, monitor interactions, and optimize your stack with AI tools.
Open DoseCraftSource Compounds
Pharma-grade, third-party tested. Our preferred vendor for the DoseCraft community.
Visit Apex PeptidesThis article is for educational and research purposes only. This protocol is based on murine data using an oxazolone-induced eczema model. It has not been validated in human clinical trials. Eczema is a complex condition — always consult a dermatologist and licensed healthcare provider before considering any protocol.
Put this research into action
Track your protocol with precision tools. Source pharma-grade compounds from a trusted vendor.
Track in DoseCraft
Build this protocol in 60 seconds. AI-powered dose logging, half-life tracking, and interaction checks.
Open Protocol BuilderGet the Compounds
Pharma-grade, third-party tested peptides from our preferred vendor. Trusted by the community.
Visit Apex PeptidesNot medical advice — educational only. DoseCraft is an information and personal tracking platform. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting any protocol. Affiliate links may be present — we only recommend vendors we trust.